Anthropometric, metabolic and clinical factors associated with diabetes and prediabetes prevalence in women aged 65–74 living in central Poland by Dereziński, Tadeusz et al.
 ORIGINAL ARTICLE ISSN 2450–7458
238
Address for correspondence:  
dr n. med. Mariusz Dąbrowski
Uniwersytet Rzeszowski, Wydział Medyczny,  
Instytut Pielęgniarstwa i Nauk o Zdrowiu
al. T. Rejtana 16C, 35–959 Rzeszów
e-mail: mariusz.dabrowski58@gmail.com
Clinical Diabetology 2019, 8, 5, 238–247
DOI: 10.5603/DK.2019.0022
Received: 26.07.2019  Accepted: 27.07.2019
Tadeusz Dereziński1, Dorota Zozulińska-Ziółkiewicz2,  
Aleksandra Uruska2, Mariusz Dąbrowski3
1Primary Care Clinic, Gniewkowo, Poland 
2Poznań University of Medical Sciences, Department of Internal Medicine and Diabetology, Raszeja Hospital, Poznań, Poland 
3University of Rzeszow, Faculty of Medicine, Institute of Nursing and Health Sciences, Rzeszów, Poland
Anthropometric, metabolic and clinical  
factors associated with diabetes  
and prediabetes prevalence in women  
aged 65–74 living in central Poland
ABSTRACT
Background. Prevalence of type 2 diabetes mellitus 
is rising worldwide. Similar trend is also observed in 
Poland, especially in elderly population. The aim of this 
cross-sectional study was to assess prevalence and to 
identify anthropometric, metabolic and clinical fac-
tors associated with diabetes and prediabetes among 
women at early elderliness living in central Poland.
Methods. 364 women aged 65–74 years, were included 
into the study. In all patients a history of diabetes and 
cardiovascular disease was obtained, blood pressure 
and anthropometric measurements were performed, 
blood samples for laboratory tests (fasting plasma 
glucose, lipid metabolism and creatinine) were drawn, 
ankle/brachial index was calculated, abdominal ultra-
sound with abdominal aorta diameter was performed 
and carotid intima/media thickness was measured. 
Data were collected during March and April 2012 in 
Gniewkowo, the rural-urban municipality in central 
Poland.
Results. 98 women had diabetes (25 de novo) and 94 
ones had prediabetes (81 de novo). Waist circumfer-
ence, BMI, lipid abnormalities as well as anthropo-
metric and metabolic indices: waist-to-height ratio 
(WHtR), triglycerides/HDL cholesterol ratio and visceral 
adiposity index (VAI) were significantly associated with 
abnormal glucose metabolism. Backward stepwise 
logistic regression analysis identified WHtR as the best 
single indicator of patients with diabetes, while again 
WHtR and VAI were the only independent indicators of 
any type of impaired glucose metabolism.
Conclusions. Abnormal glucose metabolism is highly 
prevalent among women at early elderliness, especially 
in those with visceral obesity and abnormal lipid me-
tabolism. Anthropometric and metabolic indices (WHtR 
and VAI) were better indicators of impaired glucose 
metabolism compared to separate measurements of 
single parameters. (Clin Diabetol 2019; 8, 5: 238–247)
Key words: diabetes, prediabetes, obesity, 
anthropometric parameters, metabolic parameters
Introduction
Prevalence of diabetes mellitus (DM), predomi-
nantly type 2, reached an epidemic range with 425 
million people suffering from DM worldwide in 2017 
[1]. In Poland, according to National Health Fund data, 
almost 2.34 million people (6.08% of the whole popula-
tion) were using antidiabetic medications in 2014 [2]. 
Type 2 DM is especially highly prevalent among elderly 
[3]. In South-Eastern Poland its prevalence in people 
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aged > 65 exceeded 18% of population at that age 
range (the National Health Fund data, unpublished). 
However, known DM is only a part of the problem. The 
second part is a large number of people not aware of 
having DM, and this number reaches in Europe 37.9% 
of all cases of DM [1]. Moreover, the number of people 
having impaired fasting glucose (IFG), and/or impaired 
glucose tolerance (IGT) is similar to that with DM [1]. 
It is well known that DM can lead to several negative 
long-term health consequences including increased 
risk of cardiovascular diseases, chronic kidney disease, 
visual impairment, diabetic neuropathy and cancer [4]. 
Thus, early diagnosis of DM or prediabetes (IFG and/or 
IGT) is of utmost importance for the patients’ prognosis.
The primary objective of this cross-sectional study 
was to identify the prevalence of known and un-
diagnosed glucose metabolism abnormalities: DM and 
prediabetes among women at early elderliness, living in 
a rural-urban community in central Poland. The second-
ary objective was to identify among analyzed variables 
the best indicators and predictors of overt DM as well 
as prediabetes.
Material and methods
Study participants
All women aged 65–74 years, living in Gniewkowo, 
the rural-urban community in central Poland, and be-
ing under care of a primary care clinics, were invited to 
participate in the study. We decided to choose females 
in such age range, due to high expected prevalence of 
glucose metabolism abnormalities in this population, 
and expected survival time long enough to develop 
chronic complications of diabetes — in the year 2016 
life expectancy in Poland reached 20.4 years for women 
aged 65, and 13.5 years for women aged 74 [5]. Popula-
tion of women living in this community is homogenous, 
and all invited females were of Caucasian ethnicity. In 
response to the invitation 364 women agreed to par-
ticipate in the study, which accounted for about 60% 
of all invited ones.
Data collection
Data were collected in March and April 2012. All 
women were interviewed for DM and cardiovascular 
diseases (CVD) history and also demographic data 
were collected. Then weight, height, waist and hip 
circumference were measured and upon these data 
body mass index (BMI), waist/hip ratio (WHR) and 
waist-to-height ratio (WHtR)were calculated. Women 
with BMI ≥ 25.0 kg/m2 were considered overweight 
and with BMI ≥ 30.0 kg/m2 obese. Blood pressure 
was measured by trained nursing staff with the use 
of standardized sphygmomanometer validated by the 
appropriate authorities. Measurement on the ankles 
was performed with the use of a Doppler probe and 
the ankle/brachial index (ABI) was calculated. To assess 
the cardio-metabolic risk the lowest ABI score was taken 
into analysis. Fasting blood samples were collected for 
the assessment of plasma glucose concentration, serum 
lipid profile and creatinine level, and they were analyzed 
in a certified laboratory. Estimated glomerular filtration 
rate (eGFR) was calculated using Chronic Kidney Disease 
Epidemio logy Collaboration (CKD-EPIcr) equation, cur-
rently recommended by Diabetes Poland [6, 7]:
GFR = 141 × min(Scr/k, 1)a × max(Scr/k, 1)–1.209 × 
× 0.993Age × 1.018 [if female] × 1.159 [if black]
Scr is serum creatinine [mg/dL], k is 0.7 for females and 0.9  
for males, a is –0,329 for females and –0.411 for males,  
min indicates the minimum of Scr/k or 1, and max indicates  
the maximum of Scr/k or 1
 In women with fasting plasma glucose ≥ 126 mg/dL 
measurement was repeated, while in females with 
fasting glycaemia within IFG range (100–129 mg/dL) 
oral glucose tolerance test (OGTT) was performed. DM, 
IFG or IGF were diagnosed in accordance with Diabetes 
Poland criteria from 2012 (which were identical to cur-
rent ones) [7]. Metabolic syndrome (MS) was diagnosed 
according to the most current consensus definition [8].
Upon obtained data also two metabolic indices were 
calculated: Triglycerides (TG) to HDL cholesterol (TG/ 
/HDL) ratio (expressed in mg/dL) and visceral adiposity 
index (VAI). VAI was calculated using formula developed 
by Amato et al. [9] for women: 
Also, all patients underwent abdominal ultrasound 
examination with the assessment of abdominal aorta 
diameter, and carotid intima/media thickness (CIMT) 
measurement to assess the relationship between these 
results and status of the glucose metabolism in the 
study participants. Abdominal ultrasound examina-
tion was performed using a convex transducer and the 
diameter measurement was made on the abdominal 
aorta (from renal arteries to the bifurcation). Carotid 
intima/media thickness measurement was performed 
using a linear transducer. The ultrasound measure-
ments were performed by a trained radiologists with 
the required certification for ultrasound examination. 
The highest CIMT measurement outcome was used in 
the analysis.
To avoid bias associated with failure to report of 
a 40% of the primarily invited women, 40 randomly 
selected women from that group were re-invited. They 
VAI = 
WC
36.58 + (1.89 × BMI)
×
TG
×
0.81
1.52
HDL[ [ [
[ [[
TG and HDL cholesterol expressed in mg/dL.
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reported to the clinic, where they underwent anthropo-
metric and blood pressure measurements. Their results 
were not significantly different from the first group of 
women. They were not included in the analysis, because 
they did not undergo laboratory tests, ABI measure-
ment, abdominal ultrasound and CIMT measurement.
Ethical approval
The study was approved by the Bioethics Com-
mittee at the Collegium Medicum in Bydgoszcz of the 
Nicolaus Copernicus University in Toruń and it was 
conducted in accordance with ethical standards laid 
down in an appropriate version of the Declaration of 
Helsinki and in Polish national regulations. All study 
participants signed informed consent form before 
beginning of the study procedures.
Statistical analysis
Statistical analysis of the data was performed using 
SigmaPlot for Windows, version 12.5 (Systat Software 
Inc., San Jose, CA, USA). The nominal variables are 
presented as numbers and percentage. The continuous 
data are presented as mean and standard deviation 
(SD) in parentheses. The normality of data distribution 
was checked using the Shapiro-Wilk test. Differences 
between groups (diabetes, prediabetes and normal 
glucose tolerance) were analyzed using an unpaired 
two-tailed Student’s t-test or by a Mann-Whitney rank 
sum test where appropriate. The categorical data were 
compared using c2 test. We also calculated odds ratios 
(OR) and area under curve (AUC) in receiver operating 
characteristics (ROC) curve for significant associations 
between impaired glucose metabolism and analyzed 
variables. Linear correlation between continuous vari-
ables was analyzed with the use of Spearman Rank Or-
der Correlation test. To identify predictive variables for 
glucose metabolism abnormalities we used backward 
stepwise regression analysis. We assumed a P value of 
< 0.05 as statistically significant.
Results
Impaired glucose metabolism (IGM = DM + pre-
diabetes) was found in more than half of 364 included 
women. DM was found in 98 of them and 94 females 
had prediabetes. In this number there were 25 cases of 
newly diagnosed DM and 81 new cases of prediabetes 
revealed in OGTT. Overall, 55.2% of women with IGM 
were unaware of having abnormal glucose metabolism. 
MS was present in 60.7% of cases. Impaired kidney 
function with eGFR < 60 mL/min/1.73 m2 was found 
in 37 cases (10.2% of the study participants).
We found significant differences between women 
with diabetes, prediabetes, IGM and normal glucose 
tolerance (NGT) in anthropometric parameters. BMI, 
prevalence of obesity, waist and hip circumference, 
WHR and WHtR were significantly lower in women 
with NGT, and they were increasing along with with 
the degree of glucose metabolism impairment. Women 
with DM compared to females with prediabetes had 
significantly higher BMI, WC and WHtR (Table 1).
The number of females with the history of myo-
cardial infarction (MI) was insignificantly different 
between DM and NGT groups, P = 0.051 (Table 2). 
However, women with the history of MI had over 3-fold 
higher probability of having diabetes compared to the 
rest of study participants, odds ratio (OR) 3.26, and 
95% confidence interval (CI, 1.22–8.71), P = 0.028. 
Hypertension was significantly less frequent among 
women with NGT compared to IGM and prediabetes 
groups. Women with NGT had also significantly lower 
systolic blood pressure (SBP) compared to females with 
DM, and significantly lower pulse pressure compared 
to women with DM and IGM. Diastolic blood pressure 
(DBP) was not significantly different between the study 
groups (Table 2). Although no significant differences 
were found between the groups with regards to vas-
cular parameters, we revealed, which is interesting 
finding, significantly lower abdominal aorta diameter 
in 25 women with newly diagnosed DM (upon fasting 
plasma glucose level or in OGTT) compared to females 
with known DM, prediabetes and NGT: 17.0 ± 2.5 cm 
vs. 18.6 ± 2.9 cm, 18.1 ± 2.2 cm and 18.6 ± 3.4 cm 
respectively. P values for comparisons between new DM 
vs. known DM, prediabetes and NGT were P = 0.005, 
P = 0.011 and P = 0.005 respectively. Neither ABI nor 
CIMT was significantly different between DM, predia-
betes and NGT groups (Table 2). However, we found 
borderline significant linear correlation between CIMT 
and fasting plasma glucose, R = 0.105, P = 0.046.
Kidney function was significantly worse in women 
with prediabetes and IGM compared to NGT group. 
However, number of females with eGFR ≥ 90, 60–89 
and < 60 mL/min/1.73 m2 was not significantly differ-
ent between the groups (Table 2).
All metabolic parameters and indices were signifi-
cantly different between NGT and DM or IGM groups 
(Table 3). However, females with DM were significantly 
more frequently using statins compared to women with 
prediabetes and NGT (61.2%, 37.2% and 38,4% respec-
tively), and after adjustment to statin use, differences 
between DM or IGM and NGT groups regarding total, 
non-HDL and LDL cholesterol became insignificant. 
Prevalence of MS was significantly higher in women 
with DM, prediabetes and IGM compared to NGT 
group, 90,8%, 92,6%, 91.7% and 26,2% respectively. 
Presence of MS was associated with 10-fold higher 
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probability of having DM and over 30-fold higher 
probability of having IGM compared to NGT group, OR 
10.04 (4.86–20.76), P < 0.001 and OR 31.04 (16.80– 
–57.39), P < 0.001 respectively. However, glucose level 
> 5.5 mmol/L is a both MS component and a bench-
mark of IGM, and after adjustment to this variable these 
odds ratios decreased to OR 1.76 (1.07–2.89), P = 0.034 
for DM and OR 2.10 (1.30–3.38), P = 0.003 for IGM.
All anthropometric and metabolic continuous 
variables significantly associated with abnormal glu-
cose metabolism were then included in ROC analysis, 
separately for DM and IGM. The highest area under 
curve (AUC) for DM was found for WC, WHtR and BMI, 
P < 0.001 in all cases (Figure 1A), while for IGM there 
were WC, WHtR and WHR, P < 0.001 also in all cases 
(Figure 1B). Glucose level, as a diagnostic criterion for 
DM and prediabetes was excluded from these analyses.
We analyzed also odds ratios for variables signifi-
cantly associated with the presence of DM or IGM. We 
assumed cut-off points for TG and HDL cholesterol level 
according to diagnostic criterion for MS [8], while for 
WC we took higher value, ≥ 88 cm, because 92.3% of 
all study participants had WC ≥ 80 cm. A cut-off point 
for BMI was ≥ 30 kg/m2 (obesity), for WHR > 0.85 
(abdominal obesity in women), for other variables 
cut-off points were taken from literature: VAI from 
Amato et al. [10], TG/HDL from Salazar et al., [11] and 
WHtR from Ashley & Gibson [12] or from ROC curve 
(hip circumference) (Figure 2).
In the backward stepwise regression analysis in-
cluding all anthropometric and metabolic parameters 
and indices significantly associated with abnormal 
glucose metabolism, WHtR appeared to be the only 
significant predictor of having DM, P < 0.001, while 
WHtR and VAI were the only significant predictors of 
having IGM, P < 0.001 and P = 0.005 respectively.
Discussion
Our study revealed high prevalence of overt DM 
and prediabetes in elderly women living in a rural-urban 
community in central Poland. In this number 55.2% 
were previously un diagnosed. It is in line with data 
from other countries. In the United States prevalence 
of known DM in the elderly population is reaching 
20.8%, and 4.4% have unknown DM [13]. In Canada 
prevalence of known DM among women aged 65–74 
years is estimated to be 19.4% of females in this age 
range [14]. In the United Kingdom, in the age group 
60–69 years, prevalence of DM exceeded 26% [15]. Also 
in China DM is prevalent in over 20% of elderly people, 
while IFG and/or IGT in roughly 25% [16]. Roughly, every 
one out of four people aged > 65 years suffers from 
DM. These data indicate how important epidemiologi-
cal problem is DM in the elderly. 
Both DM as well as IGT and/or IFG are associated 
with unfavorable clinical outcome including increased 
risk of cardiovascular disease (CVD) events and elevated 
CVD and all-cause mortality [17, 18]. In our study the 
Figure 1. Receiver operating characteristic (ROC) curves and area under the curve (AUC) of anthropometric and metabolic param-
eters and indices associated with the prevalence of diabetes (A) and impaired glucose metabolism (B). BMI — body mass index; 
AUC — area under curve; WC — waist circumference; WHR — waist-to-hip-ratio; WHtR — waist-to-height ratio; HDL — high 
density lipoproteins; TG — triglycerides; VAI — visceral adiposity index
BMI, AUC = 0.661
WC, AUC = 0.687
Hip, AUC = 0.636
WHR, AUC = 0.640
WHtR, AUC = 0.679
HDL, AUC = 0.582
TG, AUC = 0.590
TG/HDL, AUC = 0.587
VAI, AUC = 0.594
BMI, AUC = 0.651
WC, AUC = 0.694
Hip, AUC = 0.648
WHR, AUC = 0.654
WHtR, AUC = 0.680
HDL, AUC = 0.598
TG, AUC = 0.638
TG/HDL, AUC = 0.635
VAI, AUC = 0.645
S
e
n
s
i
v
it
y
Speciﬁcity Speciﬁcity
0,0
0,0 0,0
0,2
0,2 0,2
0,4
0,4 0,4
0,6
0,6 0,6
0,8
0,8 0,8
1,0
A B
1,0 1,0
Tadeusz Dereziński et al., Factors associated with diabetes and prediabetes in women
245
history of myocardial infarction was significantly as-
sociated with overt DM. Interestingly, we revealed also 
association between lower abdominal aorta diameter in 
women with newly diagnosed DM. In men, Taimour et 
al. did not find such a relationship [19]. Thus, this find-
ing requires further investigation. Significantly higher 
SBP and pulse pressure in women with overt diabetes 
together with lower abdominal aorta diameter can be 
considered as a clinical manifestation of the arterial 
stiffness in females with DM [20] (we did not perform 
direct measurements of pulse wave velocity and aortic 
characteristic impedance). In the Atherosclerosis Risk In 
Communities (ARIC) study low ABI was modestly but 
independently associated with diabetes incidence [21]. 
In our study ABI was not associated with any abnormal 
pattern of glucose metabolism. In the study by Gomez-
-Marcos et al. CIMT was related to HbA1c and fasting, 
but not postprandial, plasma glucose [22]. We also 
revealed relationship between fasting glycemia and 
CIMT, while we did not measure HbA1c in our study. 
MS, non-surprisingly, demonstrated in our study 
significant relationship with DM and IGM. However, 
after adjustment to elevated glucose level, this rela-
tionship became much weaker. Significant relationship 
between different components of MS and DM was also 
found by other authors [16, 23]. In these studies the 
strongest indicators of DM prevalence were elevated 
TGs, low HDL cholesterol and elevated WC. In search 
of the best anthropometric indicator of elevated “early 
health risk” Ashley and Gibson indicate WHtR as a bet-
ter indicator of this risk compared to BMI or WC alone 
[12]. In our study WHtR, although had slightly lower 
AUC than WC in the ROC curve analysis, it appeared 
to be significant predictor of prevalent DM and IGM in 
the backward stepwise analysis.
Amato et al. identified applicable indicator of 
visceral fat function based on WC, BMI, TGs and HDL 
cholesterol levels [9]. They called it Visceral Adiposity 
Index (VAI), and they developed the calculation formula 
separate for men and women. VAI can be considered 
as a predictor of cardio-metabolic risk, including dia-
betes [24, 25]. In our study females with abnormal 
glucose metabolism had significantly higher VAI score 
compared to women with NGT. The cut-off point for 
high metabolic risk (3.17) suggested by Amato et al. 
for Caucasian women aged ≥ 66 years [10] was in our 
study significantly associated with both DM and IGM 
prevalence and, together with WHtR, it was a predictor 
of prevalent IGM in the backward stepwise analysis.
Elevated TG/HDL cholesterol ratio is considered 
to be a useful tool in identifying men and women at 
high cardio-metabolic risk with a cut-off point at 2.5 
for females and 3.5 for males [11]. In our study also 
this metabolic index was significantly higher in women 
with overt DM and prediabetes compared to females 
with NGT. 
Type 2 DM is considered to be a preventable dis-
ease, both through the lifestyle as well as through the 
pharmacological interventions [26–28]. Early detection 
of IFG/IGT allows to introduce the efforts to prevent or 
at least delay diabetes development. Such strategy is 
not only beneficial for patients, but is also cost-effective 
Figure 2. Odds ratios (OR) of anthropometric and metabolic variables for the probability of having diabetes mellitus (blue) or 
impaired glucose metabolism (black) in the univariate analysis. OR — odds ratio; CI — confidence interval; BMI — body mass 
index; WHR — waist-to-hip-ratio; WHtR — waist-to-height ratio; TG — triglycerides; HDL — high density lipoproteins; VAI — 
visceral adiposity index
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3.99 (2.53–6.27) < 0.001
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[29]. Early diagnosis of DM as well allows healthcare 
providers to initiate the treatment earlier in the natural 
history of diabetes, which gives a chance to avoid the 
long-term negative consequences of the disease, which 
was documented in the United Kingdom Prospective 
Diabetes Study (UKPDS) [30]. In the meta-analysis of 
97 prospective studies involving 820,900 individuals, 
the onset of diabetes at the age of 65 was associated 
with a shortened life expectancy of almost 5 years [31]. 
Thus, screening focused on identifying people with 
abnormal glucose metabolism (in our study over 1/4 of 
women with DM were unaware of having diabetes and 
over 80% of women with prediabetes were unaware 
of this abnormality) can improve long-term prognosis 
of such persons, increase their life span and may be 
helpful in maintaining their quality of life. Moreover, 
it can be cost-effective. 
Our study is not free from several limitations. The 
first one is a relatively small number of participants. 
The second one is its cross-sectional design, which 
did not allow us to determine a causal relationship of 
revealed associations. Also a number of women with 
the history of CVD events was too small to find more 
significant associations between analyzed variables 
and clinical outcomes other than myocardial infarction. 
Finally, our study was performed solely in Caucasian 
population. Thus, our results may not be fully applicable 
to other ethnic groups. On the other hand, our study 
included representative group of females in the age 
range 65–74 living in a rural-urban municipality, and 
a wide spectrum of analyzed variables allowed us to 
find several factors associated with glucose metabo-
lism abnormalities in this population. We also found 
potential usefulness of anthropometric and metabolic 
indices other than BMI and waist circumference. 
Conclusions
Diabetes and prediabetes are highly prevalent 
among women at early elderliness, and many of them 
were unaware of having these abnormalities.
Assessment of simple anthropometric measure-
ments with the calculation of anthropometric indices 
seem to be helpful in identifying women at a high 
probability of having abnormal glucose metabolism. 
WHtR > 0.6 appeared to be the best predictor of DM, 
while WHtR > 0.6 and VAI > 3.17 were the best pre-
dictors of IGM. 
Screening aimed at the detection of diabetes 
and prediabetes in women with central obesity and 
impaired lipid metabolism is highly reasonable, and it 
should be considered as a routine procedure to early 
diagnose and to early treat women at particularly high 
CVD risk.
Long-term observation of such a population is 
required to identify significant predictors of important 
clinical outcomes (major cardiovascular events, diabetes 
and cancer incidence, and all-cause death) in the future.
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